WO2019103715A3 - Bovine malignant catarrhal fever (bmcf) immunization and the production method of the vaccine - Google Patents

Bovine malignant catarrhal fever (bmcf) immunization and the production method of the vaccine Download PDF

Info

Publication number
WO2019103715A3
WO2019103715A3 PCT/TR2018/050597 TR2018050597W WO2019103715A3 WO 2019103715 A3 WO2019103715 A3 WO 2019103715A3 TR 2018050597 W TR2018050597 W TR 2018050597W WO 2019103715 A3 WO2019103715 A3 WO 2019103715A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
bmcf
immunization
production method
catarrhal fever
Prior art date
Application number
PCT/TR2018/050597
Other languages
French (fr)
Other versions
WO2019103715A2 (en
Inventor
Bilge Kaan TEKELIOGLU
Original Assignee
Celik, Mehmet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celik, Mehmet filed Critical Celik, Mehmet
Publication of WO2019103715A2 publication Critical patent/WO2019103715A2/en
Publication of WO2019103715A3 publication Critical patent/WO2019103715A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention relates to an autologous and homologous pulverized mucosal vaccine produced for the purpose of immunizing and treating against bovine malignant catarrhal fever infection (BMCF, Coryza Gangrenosa Bovum) and the method of producing the vaccine.
PCT/TR2018/050597 2017-11-27 2018-10-17 Bovine malignant catarrhal fever (bmcf) immunization and the production method of the vaccine WO2019103715A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2017/18859 2017-11-27
TR2017/18859A TR201718859A2 (en) 2017-11-27 2017-11-27 VACCINE AND VACCINE PRODUCTION METHOD FOR GANGRENOUS MONITORING OF CATTLE

Publications (2)

Publication Number Publication Date
WO2019103715A2 WO2019103715A2 (en) 2019-05-31
WO2019103715A3 true WO2019103715A3 (en) 2019-06-27

Family

ID=66630783

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050597 WO2019103715A2 (en) 2017-11-27 2018-10-17 Bovine malignant catarrhal fever (bmcf) immunization and the production method of the vaccine

Country Status (2)

Country Link
TR (1) TR201718859A2 (en)
WO (1) WO2019103715A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110967483B (en) * 2019-12-27 2023-10-27 霸州市砚创科技有限公司 Detection kit for malignant catarrhal fever virus, preparation method and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053477A1 (en) * 2001-12-21 2003-07-03 Baxter International Inc. Process for inactivating pathogens in a biological solution
WO2007104562A1 (en) * 2006-03-15 2007-09-20 Universiteit Gent Dry powder compositions and systems for poultry vaccination
WO2009061409A1 (en) * 2007-11-06 2009-05-14 Hemcon Medical Technologies, Inc. Stable solutions having antiviral, antibacterial, and hemostatic properties and methods of making thereof
WO2010062757A1 (en) * 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003053477A1 (en) * 2001-12-21 2003-07-03 Baxter International Inc. Process for inactivating pathogens in a biological solution
WO2007104562A1 (en) * 2006-03-15 2007-09-20 Universiteit Gent Dry powder compositions and systems for poultry vaccination
WO2009061409A1 (en) * 2007-11-06 2009-05-14 Hemcon Medical Technologies, Inc. Stable solutions having antiviral, antibacterial, and hemostatic properties and methods of making thereof
WO2010062757A1 (en) * 2008-11-03 2010-06-03 Ligocyte Pharmaceuticals, Inc. Improved methods for isolating enveloped virus-based vlps free of infectious agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HAIG, DAVID M. ET AL.: "An immunisation strategy for the protection of cattle against alcelaphine herpesvirus-1-induced malignant catarrhal fever", VACCINE, vol. 26.35, 2008, pages 4461 - 4468, XP023520858 *

Also Published As

Publication number Publication date
WO2019103715A2 (en) 2019-05-31
TR201718859A2 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
PH12019501552A1 (en) Polypeptide-antigen conjugates with non-natural amino acids
MX2023007841A (en) Crispr-cpf1-related methods, compositions and components for cancer immunotherapy.
MX2020009366A (en) Anti-cd73 antibodies and uses thereof.
MX2019005465A (en) Immunotherapeutic tumor treatment method.
MX2018015853A (en) Multispecific antibodies against cd40 and cd137.
EP3800248A3 (en) Crispr-cas-related methods, compositions and components for cancer immunotherapy
MX350661B (en) Yeast-brachyury immunotherapeutic compositions.
EA201391496A1 (en) IMMUNOGENIC COMPOSITIONS AND METHODS OF APPLICATION OF SUCH COMPOSITIONS FOR INDUCTION OF HUMORAL AND CELLULAR IMMUNE RESPONSE
EA201892485A1 (en) METHOD FOR PRODUCING DIARYLTHIOHYDANTOIN COMPOUND
MX2017000630A (en) Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector.
MX352892B (en) Yeast-muc1 immunotherapeutic compositions and uses thereof.
PH12020500329A1 (en) Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
MX2017001946A (en) Anti-cdh6 antibody drug conjugates.
ZA201900070B (en) Antibodies with low immunogenicity and uses thereof
MX2020011914A (en) Anti-dll3 antibodies and uses thereof.
AU2015348922A8 (en) Codon optimized polynucleotide for high level expression of CRM197
GB201017519D0 (en) Vaccines
MX2017003301A (en) Refractory product, batch composition for producing said product, method for producing the product and use of said product.
PL409076A1 (en) Method for obtaining 4'-methoxy-4-methyl α, β-dihydrochalcone
UA117826C2 (en) Batch composition for producing an unshaped refractory ceramic product, method for producing a fired refractory ceramic product, fired refractory ceramic product, and use of an unshaped refractory ceramic product
MX2023007003A (en) Tissue-specific antigens for cancer immunotherapy.
MX2021012201A (en) Water soluble adjuvant.
WO2019103715A3 (en) Bovine malignant catarrhal fever (bmcf) immunization and the production method of the vaccine
MX2021012200A (en) Water soluble adjuvant and composition containing same.
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18881139

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18881139

Country of ref document: EP

Kind code of ref document: A2